Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.17 | 11.724137931 | 1.45 | 1.6394 | 1.4 | 1118655 | 1.46407238 | CS |
| 4 | 0.08 | 5.19480519481 | 1.54 | 1.6394 | 1.23 | 1295189 | 1.42391535 | CS |
| 12 | -0.96 | -37.2093023256 | 2.58 | 2.84 | 1.23 | 1297095 | 1.76066073 | CS |
| 26 | -1.28 | -44.1379310345 | 2.9 | 3.305 | 1.23 | 1398009 | 2.34560963 | CS |
| 52 | -0.55 | -25.3456221198 | 2.17 | 3.45 | 1.23 | 1694341 | 2.48183293 | CS |
| 156 | -9.52 | -85.4578096948 | 11.14 | 11.21 | 1.23 | 1084746 | 3.22919605 | CS |
| 260 | -14.28 | -89.8113207547 | 15.9 | 24.47 | 1.23 | 985830 | 4.46094876 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
